Research programme: anti-cancer therapeutics - Zestagen

Drug Profile

Research programme: anti-cancer therapeutics - Zestagen

Alternative Names: mAb 4C5; ZSG 101; ZSG 102; ZSG 103

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hellenic Pasteur Institute
  • Developer Hellenic Pasteur Institute; Zestagen
  • Class Monoclonal antibodies
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Breast cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 28 Nov 2016 Early research in Non-small cell lung cancer in Switzerland (unspecified route)
  • 28 Nov 2016 Zestagen plans a phase I trial before November 2016
  • 25 Nov 2016 Research programme: anti-cancer therapeutics - Zestagen is seeking series A financing as of 25 Nov 2016.; 3210352
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top